Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide
Endocrine Society • • general
Key Points:
- Polycystic Ovary Syndrome (PCOS), affecting over 170 million women globally, has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect the condition's complexity and hormonal nature.
- The name change, led by Professor Helena Teede and involving over 50 patient and professional organizations, addresses misconceptions about ovarian cysts and emphasizes metabolic and endocrine factors.
- Research has shown no increase in abnormal ovarian cysts in the condition, supporting the need for the updated name and improved diagnostic and treatment approaches.
- The renaming process took 14 years of global collaboration, including extensive patient input, and will be fully implemented in the 2028 International Guideline update alongside an international education campaign.
- The new name aims to reduce stigma, improve cultural sensitivity, and enhance awareness and care for those affected, marking a significant advancement in clinical practice and research.